Perfect IPO Capsule: Senores Pharma Issue Subscribed 93.41 times

Retail Portion was subscribed 89.21 times and Non-Institutional Investors segment 96.11 times.
MUMBAI, Dec 24 (The CONNECT)- The Initial Public Offering of Senores Pharmaceuticals Limited was subscribed 93.41 times, data available on the final day of bidding, today, shows.
The issue received bids of 79,72,11,576 shares against the offered 85,34,681 equity shares, at a price band of ₹372-391.
Retail Portion and Non-Institutional Investors Portion were subscribed 89.21 times and 96.11 times respectively, whereas Qualified Institutional Buyer Portion was subscribed 94.66 times. Employee Portion was subscribed 19.92 times.
Equirus Capital Private Limited, Ambit Private Limited, and Nuvama Wealth Management Limited are the book-running lead managers, and Link Intime India Private Limited is the registrar of the issue.
Company Information
Senores Pharmaceuticals operates a critical care injectables business, supplying critical care injectables to hospitals across India through distributors, and manufacture APIs for the domestic market and SAARC countries.
It identifies, develops, and manufactures a wide range of specialty and complex pharmaceutical products, making it a preferred partner for key customers.
By leveraging data analytics, research, and its experienced management, the company strategically targets underpenetrated molecules in both Regulated and Emerging Markets. Its strong R&D capabilities enable the development of differentiated products, with a focus on quality and complex molecules.
The company has built a robust pipeline, demonstrated through partnerships in the US, Canada, and the UK with major pharmaceutical companies such as Prasco LLC, Jubilant Cadista Pharmaceuticals, Alkem Laboratories Limited, Sun Pharmaceuticals Industries Limited, Dr. Reddy’s Laboratories Inc., and Cipla USA Inc.
The Company primarily focused on Regulated Markets in the US, Canada, and the UK, also has a presence in 43 Emerging Markets. Its business operates under two models for its Regulated Markets Business: Marketed Products (including ANDA and sourced products) and contract development and manufacturing operations contract manufacturing operations.
The company’s portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline.